Immunité anti-tumorale et thérapies cellulaires du cancer, Med Sci (Paris), vol.19, pp.43-53, 2003. ,
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy, Clin Cancer Res, vol.17, pp.4550-4557, 2011. ,
Lymphocytes T?? en cancérologie : des lymphocytes tueurs non conventionnels, Med Sci, vol.26, pp.185-91, 2010. ,
Adoptive immunotherapy for cancer, Immunol Rev, vol.257, pp.14-38, 2014. ,
Driving cars to the clinic for solid tumors, Gene Ther, vol.25, pp.165-75, 2018. ,
Therapeutic T cell engineering, Nature, vol.545, pp.423-454, 2017. ,
CAR T cells in trials : Recent achievements and challenges that remain in the production of modified T cells for clinical applications, Hum Gene Ther, vol.29, pp.559-68, 2018. ,
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity, Proc Natl Acad Sci, vol.86, pp.10024-10032, 1989. ,
Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain, J Exp Med, vol.178, pp.361-367, 1993. ,
T-cell clones can be rendered specific for CD19 : toward the selective augmentation of the graft-versus-B-lineage leukemia effect, Blood, vol.101, pp.1637-1681, 2003. ,
Virus-specific T cells engineered to coexpress tumor-specific receptors : persistence and antitumor activity in individuals with neuroblastoma, Nat Med, vol.14, pp.1264-70, 2008. ,
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, vol.116, pp.4099-102, 2010. ,
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, vol.365, pp.725-758, 2011. ,
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci Transl Med, vol.5, pp.177-215, 2013. ,
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, vol.6, pp.224-249, 2014. ,
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci Transl Med, vol.7, pp.303-139, 2015. ,
Immunothérapie « CAR-T » : une autorisation qui fait date, Med Sci, vol.33, pp.1003-1009, 2017. ,
, Biol Blood Marrow Transplant, vol.24, pp.27-31, 2018.
Driving gene-engineered T cell immunotherapy of cancer, Cell Res, vol.27, pp.38-58, 2017. ,
Considerations for clinical review of cellular therapy products : perspectives of the china food and drug administration center for drug evaluation, Hum Gene Ther, vol.29, pp.121-128, 2018. ,
The principles of engineering immune cells to treat cancer, Cell, vol.168, pp.724-764, 2017. ,
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci Transl Med, vol.9, 2017. ,
Engineered CAR T cells targeting the cancer-associated tn-glycoform of the membrane mucin MUC1 control adenocarcinoma, Immunity, vol.44, pp.1444-54, 2016. ,
CAR T cell therapy for solid tumors, Annu Rev Med, vol.68, pp.139-52, 2017. ,
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity, Cancer Immunol Res, vol.3, pp.125-160, 2015. ,
Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T Cells, Immunity, vol.44, p.712, 2016. ,
Cancer immunotherapy using checkpoint blockade, Science, vol.359, pp.1350-1355, 2018. ,
Les récepteurs de nectines/nectines-like DNAM-1 et CRTAM. Immuno-surveillance ou échappement tumoral ?, Med Sci, vol.30, pp.537-580, 2014. ,
Tim-3. Biomarqueur et cible thérapeutique en cancérologie, Med Sci, vol.34, pp.231-238, 2018. ,
Lag-3, Tim-3, and TIGIT : Co-inhibitory receptors with specialized functions in immune regulation, Immunity, vol.44, pp.989-1004, 2016. ,
The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, vol.12, pp.252-64, 2012. ,
Elements of cancer immunity and the cancer-immune set point, Nature, vol.541, pp.321-351, 2017. ,